Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Deciphera Pharmaceuticals's Vimseltinib?
Vimseltinib is a small molecule commercialized by Deciphera Pharmaceuticals, with a leading Phase III program in Tenosynovial Giant Cell Tumor....
Vimseltinib by Deciphera Pharmaceuticals for Tenosynovial Giant Cell Tumor: Likelihood of Approval
Vimseltinib is under clinical development by Deciphera Pharmaceuticals and currently in Phase III for Tenosynovial Giant Cell Tumor. According to...
Risk adjusted net present value: What is the current valuation of Deciphera Pharmaceuticals's Vimseltinib?
Vimseltinib is a small molecule commercialized by Deciphera Pharmaceuticals, with a leading Phase III program in Tenosynovial Giant Cell Tumor....